Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on May 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Zachary Roberts becomes CEO and President July 1, 2026, replacing David Chang.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Zachary Roberts becomes CEO and President July 1, 2026, replacing David Chang
- Roberts adds Class I board seat through 2028 annual meeting while continuing as interim Chief Medical Officer
- Chang remains a director and becomes non-employee director, eligible for board compensation and severance benefits
- CEO package includes $680,000 salary, 60% target cash incentive, 476,190-stock option, and 134,530-share RSU award
- Leadership transition places an experienced internal R&D executive in control, limiting near-term operational disruption
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.